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Seven blaIMP-1-harboring Acinetobacter sp. isolates and one Pseudomonas putida clinical isolate were recov-
ered from hospitalized patients. All isolates possessed a class 1 integron, named In86, carrying the same
cassette array [blaIMP1, aac(6)-31, and aadA1], which was plasmid located in five of the isolates. This report
describes the ability of nonfermentative nosocomial pathogens to acquire and disseminate antimicrobial
resistance determinants.
Metallo--lactamases (MLs) and aminoglycoside-modify-
ing enzymes (AgMEs) represent a new challenge to antimicro-
bial therapy of nosocomial infections, since they confer phe-
notypic resistance to nearly all clinically available -lactams
and aminoglycosides, respectively (1). Several ML and ami-
noglycoside resistance genes in nosocomial isolates recovered
from Latin American countries have been described previously
(7, 8, 9); however, there is limited information regarding the
dissemination of these genes in this region. In the present
study, we describe a new blaIMP-1-carrying integron that con-
tains a new aminoglycoside resistance gene and its dissemina-
tion among genetically unrelated clinical isolates recovered
from a Brazilian hospital.
As part of the SENTRY Antimicrobial Surveillance Pro-
gram (12), gram-negative bacilli recovered from Latin Amer-
ican hospitals between March 2001 and April 2003 were tested
for antimicrobial susceptibility by reference methods according
to standard guidelines (3, 4). Strains showing combined resis-
tance to ceftazidime (MIC, 16 g/ml), imipenem (MIC, 16
g/ml), and meropenem (MIC, 16 g/ml) were routinely
screened for ML genes by standards PCRs (2, 9, 11). Seven
Acinetobacter sp. isolates and one Pseudomonas putida clinical
isolate recovered from a 600-bed tertiary university hospital
located in Sa˜o Paulo, Brazil, were found to harbor blaIMP-1 and
were further evaluated in the present study (Table 1).
In general, the evaluated isolates showed a decreased sus-
ceptibility or resistance phenotype to mostly all the antimicro-
bial agents tested, showing susceptibility only to polymyxin B,
and some isolates also showed susceptibility to quinolones
(Table 1). A genotypic comparison of the blaIMP-1-harboring
Acinetobacter sp. isolates was performed using the RiboPrinter
microbial characterization system and pulsed field-gel electro-
phoresis (PFGE), as previous described (12). Acinetobacter sp.
isolates 694 and 696 showed identical PFGE patterns, while
isolates 9043 and 695 differed from each other in less than five
bands (similar PFGE patterns), and they were considered to
belong to the same ancestor. The remaining Acinetobacter spp.
showed distinct PFGE patterns and were considered to be
unrelated (16). In summary, five different clones were observed
among the seven Acinetobacter sp. isolates (Table 1).
The blaIMP-1-containing integrons were amplified by PCR
and sequenced using primers targeting the 5 conserved se-
quences (CS) and 3 CS of class 1 integrons (2, 9). All isolates
possessed the same class 1 integron cassette arrangement, des-
ignated In86. This integron harbored blaIMP-1 at the first po-
sition downstream of the 5 CS, followed by an open reading
frame of 519 bp identified as a new AgME gene cassette. This
gene, designated aac(6)-31, was followed by another AgME
gene cassette, namely, aadA1 (Fig. 1). aac(6)-31 potentially
encoded a protein of 173 amino acids (19.1 kDa), which ex-
hibited the highest identity (82.1%) to AAC(6)-Ib (GenBank
accession number CAE48336) (Fig. 2), encoded by the blaIMP-16-
carrying Pseudomonas aeruginosa integron isolated from Brası´lia,
Brazil (9), 630 miles from Sa˜o Paulo, suggesting that these two
genes could be derived from a common ancestor.
To evaluate the flanking DNA sequences upstream of In86,
these regions were sequenced using a random primer PCR
approach as previously described (15). The 5 CS of In86 in the
P. putida isolate contained the integrase gene, which was
bound by a Tn402-like 25-bp IRi sequence. The DNA se-
quence upstream of the 25-bp IRi did not show any homology
with previously deposited sequences in the GenBank database
(Fig. 1 and 3). However, all the Acinetobacter sp. isolates
showed the same DNA insertion just downstream of the In86
integrase gene, which was inserted between the i2 and i3 19-bp
repeats that are usually present in the internal region of the IRi
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FIG. 1. Schematic representation of the blaIMP-1-containing class 1 integron found in P. putida and Acinetobacter sp. Inserted genes are
indicated by boxes, and the arrows indicate their transcriptional orientations. Boxes with horizontal and vertical bars represent the inserted DNA
sequences found upstream of the In86 25-bp IRi in the P. putida strain and in the In86 5 CS in the Acinetobacter sp. strains, respectively.
TABLE 1. Clinical and antimicrobial profile and molecular information from the clinical isolates harboring blaIMP-1-carrying In86 evaluated
in the present study
Parameter
Value
A. baumannii
694
A. baumannii
696
A. baumannii
9043
A. baumannii
695
A. baumannii
501
Acinetobacter sp.
strain 5227
Acinetobacter sp.
strain 5248
P. putida
12346
Sample collection date
(mo/day/yr)
05/28/2002 06/04/2002 06/22/2001 06/02/2002 05/06/2001 08/14/2002 09/28/2002 07/23/2001
Source SSTIb SSTIb BSIc SSTIb BSIc LRTId LRTId BSIc
MIC (g/ml)a
-Lactam
Aztreonam 16 16 16 16 16 16 16 16
Ampicillin 16 16 16 16 16 16 16 16
Amoxicillin-
clavulanate
16 16 16 16 16 16 16 16
Aztreonam 16 16 16 16 16 16 16 16
Ceftazidime 16 16 16 16 16 16 16 16
Piperacillin 128 128 128 128 32 128 128 64
Piperacillin-
tazobactam
32 64 64 64 64 64 64 64
Ticarcillin 128 128 128 128 128 128 128 128
Ticarcillin-
clavulanate
128 128 128 128 128 128 128 128
Cefepime 16 16 16 16 16 16 16 16
Imipenem 8 8 8 8 8 8 8 8
Meropenem 8 8 8 8 8 8 8 8
Aminoglycoside
Amikacin 32 32 32 32 32 32 32 32
Gentamicin 8 8 8 8 8 8 8 8
Netilmycin 32 32 32 8 32 32 16 32
Tobramycin 16 16 16 16 16 16 8 16
Quinolone
Levofloxacin 0.25 0.25 4 4 0.25 2 4 4
Gatifloxacin 0.25 0.06 4 4 0.12 1 4 4
Ciprofloxacin 1 0.5 2 4 0.12 2 4 2
Polymyxin B 1 1 1 1 1 1 1 1
blaIMP-1 location Plasmidial Plasmidial Plasmidial Plasmidial Plasmidial Chromosomal Plasmidial Chromosomal
Ribotyping 258.105.2 258.105.2 105.815.4 105.815.4 252.43.4 258.148.6 258.148.2 NAe
PFGE PSA48A PSA48A PSA48B PSA48B1 PSA48C PSA48D PSA48E NAe
a Interpretive criteria for the antimicrobial tested were those published by the Clinical and Laboratory Standard Institute (CLSI) (formerly National Committee for
Clinical Laboratory Standards) (4).
b SSTI, skin and soft tissue infection.
c BSI, bloodstream infection.
d LRTI, lower respiratory tract infection.
e NA, not applicable.
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(13) (Fig. 1 and 3). This sequence also did not possess homol-
ogy with previously reported DNA sequences. Moreover, Acin-
etobacter sp. isolate 501 showed a second DNA insertion just
upstream of the previous one, which was revealed to be a
terminal inverted repeat, IS1006.1, located 138 bp upstream of
the IRi. IS1006.1 was closely related to the terminal repeat of
IS26, IS1006, IS1007, IS1009, and IS1010 followed by the exact
last 39 nucleotides of the tnp1006 gene (Fig. 3). This structure
showed the highest identity to a similar region in the Acineto-
bacter lwoffii plasmid pKLH202 (GenBank accession number
AJ486857) (5). These findings suggest that the integron found
in the P. putida strain was likely to be the progenitor blaIMP-1-
carrying integron circulating in this nosocomial environment.
Repeated electroporation and conjugation experiments of
putative plasmid DNA extracts from the blaIMP-1-containing
strains, performed as previously described (9), failed. Despite
several preparations, the presence of plasmid DNA was not
observed in P. putida and in Acinetobacter sp. isolate 5227,
suggesting a chromosomal location. The remaining isolates
showed several plasmids (data not shown), which were recog-
nized by a blaIMP-1-specific probe in a Southern blot experi-
ment (14), suggesting that In86 was plasmid located in those
isolates (data not shown). The blaIMP-1 probe recognized plas-
mids showing similar sizes, apart from Acinetobacter sp. isolate
501, which seemed to possess a slightly smaller blaIMP-1-carry-
ing DNA plasmid. These hybridization profiles were in agree-
ment with the sequencing results, which showed an identical
structure downstream of the integrase gene in those Acineto-
bacter sp. isolates except for Acinetobacter sp. isolate 501, sug-
gesting a distinct genetic locus in the latter strain.
To determine the functionality of aac(6)-31, the gene was
amplified by PCR and ligated into a pPCRScriptCam SK()
vector to construct the recombinant plasmid pIMPAR-31 as
previously described (9). This plasmid was subsequently trans-
FIG. 2. Comparison of the deduced amino acid sequences of the most similar proteins compared to AAC(6)-31. Differences in the amino acid
sequences are noted by the insertion of a single letter representing the amino acid change within that particular sequence. GenBank accession
numbers for each sequence are as follows: AAA25685 for AAC(6)-Ib (6) and CAE48336 for AAC(6)-Ib (9).
FIG. 3. Nucleotides and amino acid sequences of the In86 5 CS found in the studied strains. Asterisks and horizontal arrows indicate the stop
codon and the transcription direction of the partial open reading frames, respectively. The corresponding predicted protein translation is reported
below the DNA sequence. The IS26 15-bp inverted repeat is boxed, and the IRi and the i1 to i4 inverted repeats typical of the 5 CS of Tn402-like
elements are also indicated. The hypothetical 8-bp direct repeat of IS26 is in boldface type.
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ferred into Escherichia coli DH5 cells, and the recombinant
strain was tested for susceptibility against several aminoglyco-
sides (Table 2). aac(6)-31 expressed in E. coli DH5 cells
conferred decreased susceptibility to all aminoglycosides eval-
uated, including gentamicin, tobramycin, kanamycin, amikacin,
neomycin, netilmicin, sisomicin, and isepamicin. MICs were 8-
to 32-fold higher than those for E. coli DH5 (Table 2). This
phenotype has not been described previously but was observed
only when different AgME genes were expressed in combina-
tions. This suggests that the expression of aac(6)-31 may be
sufficient to confer resistance to all clinically available amino-
glycosides, and this gene may gradually replace other aac(6)
family genes commonly found among nonfermentative patho-
gens. A similar situation was previously observed among bac-
terial strains recovered from Turkey (10).
The presence of five genetically unrelated Acinetobacter sp.
strains and one P. putida strain, sharing a common blaIMP-1-
carrying integron during the study period, shows the ability of
nonfermentative nosocomial strains to acquire and subse-
quently spread antimicrobial resistance determinants. This
may be the reason for the continuing recovery of blaIMP-1-
harboring P. aeruginosa and Acinetobacter sp. strains in this
hospital.
Nucleotide sequence accession numbers. The nucleotide se-
quences of the blaIMP-1-containing integron described in this
paper have been submitted to the EMBL/GenBank/DNA Data
Bank of Japan sequence databases and assigned the accession
numbers AM283489 (P. putida), AM283490 (Acinetobacter
baumannii strain 501), and AJ640197 (Acinetobacter sp. strains
695, 696, 5227, 9043, and 5248).
We thank Rosa Maria Silva and Renata Cristina Pica˜o for their
excellent technical contribution to the manuscript.
H. S. Sader and R. N. Jones have received research/education grants
in the last 3 years from AB BIODISK, Abbott, AlamX, Arpida,
AstraZeneca, Avexa, Basilea, Bayer, Becton Dickinson, Beninger-
Ingelheim, bioMerieux, Bristol-Myers Squibb, Cadence, Cerexa, Chiron,
Cognigen, Cubist, Daiichi, Elan, Elanco, Enanta, GlaxoSmithKline,
Intrabiotics, Johnson & Johnson, LG Chemicals, Merck, Micrologix,
Novartis, Optimer, Ordway, Oscient, Osmotics, Peninsula, Pfizer,
Replidyne, Schering-Plough, Sequoia, Serenex, Shionogi, Theravance,
TREK Diagnostics, Vicuron, and Wyeth.
REFERENCES
1. Bush, K., and G. H. Miller. 1998. Bacterial enzymatic resistance: -lactama-
ses and aminoglycoside-modifying enzymes. Curr. Opin. Microbiol. 1:509–
515.
2. Castanheira, M., M. A. Toleman, R. N. Jones, F. J. Schmidt, and T. R.
Walsh. 2004. Molecular characterization of a -lactamase gene, blaGIM-1,
encoding a new subclass of metallo--lactamase. Antimicrob. Agents Che-
mother. 48:4654–4661.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically. Docu-
ment M7-A7. CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2006. Performance standards
for antimicrobial susceptibility testing, 16th informational supplement
M100-S16. CLSI, Wayne, PA.
5. Kholodii, G., S. Mindlin, Z. Gorlenko, M. Petrova, J. Hobman, and V.
Nikiforov. 2004. Translocation of transposition-deficient (TndPKLH2-like)
transposons in the natural environment: mechanistic insights from the study
of adjacent DNA sequences. Microbiology 150:979–992.
6. Lambert, T., M. C. Ploy, and P. Courvalin. 1994. A spontaneous point
mutation in the aac(6)-Ib gene results in altered substrate specificity of
aminoglycoside 6-N-acetyltransferase of a Pseudomonas fluorescens strain.
FEMS Microbiol. Lett. 115:297–304.
7. Lincopan, N., J. A. McCulloch, C. Reinert, V. C. Cassettari, A. C. Gales, and
E. M. Mamizuka. 2005. First isolation of metallo--lactamase-producing
multiresistant Klebsiella pneumoniae from a patient in Brazil. J. Clin. Micro-
biol. 43:516–519.
8. Mendes, R. E., M. Castanheira, P. Garcia, M. Guzman, M. A. Toleman, T. R.
Walsh, and R. N. Jones. 2004. First isolation of blaVIM-2 in Latin America:
report from the SENTRY Antimicrobial Surveillance Program. Antimicrob.
Agents Chemother. 48:1433–1434.
9. Mendes, R. E., M. A. Toleman, J. Ribeiro, H. S. Sader, R. N. Jones, and T. R.
Walsh. 2004. Integron carrying a novel metallo--lactamase gene, blaIMP-16,
and a fused form of aminoglycoside-resistant gene aac(6)-30/aac(6)-Ib:
report from the SENTRY Antimicrobial Surveillance Program. Antimicrob.
Agents Chemother. 48:4693–4702.
10. Over, U., D. Gur, S. Unal, and G. H. Miller. 2001. The changing nature of
aminoglycoside resistance mechanisms and prevalence of newly recognized
resistance mechanisms in Turkey. Clin. Microbiol. Infect. 7:470–478.
11. Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J. D. Cavallo, and P.
Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing
metallo--lactamase and its plasmid- and integron-borne gene from a
Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Che-
mother. 44:891–897.
12. Ribeiro, J., R. E. Mendes, R. Domingos, E. Franca, S. Silbert, R. N. Jones,
and H. S. Sader. 2006. Microbiological and epidemiological characterization
of imipenem-resistant Pseudomonas aeruginosa strains from a Brazilian ter-
tiary hospital: report from the SENTRY Antimicrobial Surveillance Pro-
gram. J. Chemother. 18:461–467.
13. Riccio, M. L., L. Pallecchi, J. D. Docquier, S. Cresti, M. R. Catania, L.
Pagani, C. Lagatolla, G. Cornaglia, R. Fontana, and G. M. Rossolini. 2005.
Clonal relatedness and conserved integron structures in epidemiologically
unrelated Pseudomonas aeruginosa strains producing the VIM-1 metallo--
lactamase from different Italian hospitals. Antimicrob. Agents Chemother.
49:104–110.
14. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory
manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
NY.
15. Sorensen, A. B., M. Duch, P. Jorgensen, and F. S. Pedersen. 1993. Ampli-
fication and sequence analysis of DNA flanking integrated proviruses by a
simple two-step polymerase chain reaction method. J. Virol. 67:7118–7124.
16. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray,
D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA
restriction patterns produced by pulsed-field gel electrophoresis: criteria for
bacterial strain typing. J. Clin. Microbiol. 33:2233–2239.
TABLE 2. Aminoglycoside susceptibility profiles of E. coli DH5-harboring recombinant plasmid pIMPAR-31 and the
recipient strain E. coli DH5
E. coli plasmid
or strain
MIC (g/ml)
Gentamicin Amikacin Kanamycin Neomycin Netilmicin Sisomicin Isepamicin Tobramycin
pIMPAR-31 4 8 16 8 4 8 4 4
DH5 0.25 0.5 0.5 0.25 0.5 0.25 0.12 0.25
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